Advanced Cancer Clinical Trials

A listing of 51 Advanced Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Advanced Cancer

1 - 12 of 51

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 51 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

NCT06548672

Recruiting

This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/09/2024

Locations: Case Western Reserve University, Cleveland, Ohio

Conditions: Advanced Cancer, Metastatic Solid Tumor

Learn More ›

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005

Recruiting

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/04/2025

Locations: Sarah Cannon Research Center, Nashville, Tennessee +2 locations

Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor

Learn More ›

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/03/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +19 locations

Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)

Learn More ›

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575

Recruiting

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/30/2025

Locations: Providence Medical Foundation - Research, Santa Rosa, California +111 locations

Providence Medical Foundation - Research, Santa Rosa, California

Local Institution - 104, Chicago, Illinois

Local Institution - 103, Minneapolis, Minnesota

Kansas City VA Hospital, Kansas City, Missouri

Veterans Affairs Medical Center (VAMC) - Durham - Oncology, Durham, North Carolina

VA North Texas Healthcare System/Dallas VA Medical Center, Dallas, Texas

Hospital Sao Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul

Clinica de Neoplasias Litoral, Itajaí, Santa Catarina

Oncocentro Belo Horizonte, Belo Horizonte, São Paulo

AMO Assistencia Multidisciplinar em Oncologia, Salvador, Not set

A.C. Camargo Cancer Center, São Paulo, Not set

Klinički bolnički centar Sestre milosrdnice, Zagreb, Grad Zagreb

Local Institution - 525, Pula, Istarska Županija

Hopital Haut-Leveque - Maladies respiratoires, Pessac, Gironde

Institut de Cancerologie de I'Ouest - Service d'Oncologie Medicale - Service d'Oncologie Médicale, Saint-Herblain Cedex, Loire-Atlantique

Centre Hospitalier Universitaire D' Angers Hôpital Larrey - PNEUMOLOGIE, Angers, Maine-et-Loire

Centre Hospitalier Universitaire de Poitiers - Service d'oncologie Médicale Oncologie Medicale - Cancerolo, Poitiers, Poitou-Charentes

CHU de Grenoble, Grenoble, Rhône-Alpes

AP-HM Hopital Nord, Marseille, Rhône

Centre Hosptalier De Villefranche-Sur-Saone - Oncologie Medicale - Cancerolo, Villefranche Sur Saone, Rhône

Centre Hôspitalier de Bretagne Sud - Hôpital du Scorff, Lorient, Not set

CHU de Nantes - Hôpital Nord Laënnec (HGRL), Nantes cedex 1, Not set

Centre Hospitalier de Cornouaille, Quimper, Not set

Hôpital Bégin - Service d'Oncologie, Saint-Mandé, Not set

University of Patras, Patra, Achaïa

General Hospital of Athens "Alexandra", Athens, Attiki

Local Institution - 582, Athens, Attiki

University General Hospital Attikon, Haidari - Athens, Attiki

St. Luke's Hospital S.A., Panorama, Not set

Theageneio Cancer Hospital, Thessaloniki, Not set

General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Not set

Local Institution - 600, Szolnok, Jász-Nagykun-Szolnok

Bnai Zion Medical Center Rheumatology Unit, Haifa, Tel-Aviv

Assuta Medical Center, Tel Aviv-Yafo, Tel-Aviv

Shaare Zedek Medical center - Oncology, Jerusalem, Yerushalayim

Rambam Health Care Campus, Haifa, Not set

Tel Aviv Sourasky Medical Center - Oncology - Hematology/Oncology, Tel-Aviv, Not set

Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro, Pesaro E Urbino

Azienda Ospedaliero-Universitaria Maggiore Della Carita, Novara, Piemonte

Istituto di Candiolo, IRCCS, Candiolo, Torino

IEO - Istituto Europeo di Oncologia, IRCCS, Milano, Not set

Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia, Perugia, Not set

Istituto Nazionale Tumori Regina Elena - IRCCS - IFO, Roma, Not set

Local Institution - 401, Toon, Ehime

Local Institution - 403, Nishinomiya, Hyôgo [Hyogo]

National Cancer Center, Goyang-Si, Gyeonggido [Kyonggi-do]

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Gangnam Severance Hospital - Oncology, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Local Institution - 128, Tuxtla Gutiérrez, Chiapas

Local Institution - 125, Toluca, Not set

Local Institution - 802, Breda, Noord-Brabant

Anthoni van Leeuwenhoek Ziekenhuis, Nederlands Kanker Instit, Amsterdam, Noord-Holland

St. Antonius Hospital, Utrecht, Not set

Local Institution - 152, San Martin de Porres, Lima

Local Institution - 129, Krakow, Malopolskie

Pratia MCM Krakow, Krakow, Malopolskie

Szpitale Pomorskie Sp. z o.o. - Oddzial Onkologii i Radioterapii - Oddzial Onkologii Klinicznej, Gdynia, Pomorskie

MS Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Sp. Jawna, Lublin, Not set

Medisprof - Medical Oncology, Cluj-Napoca, Cluj

Ovidius Clinical Hospital, Ovidiu, Constanta

Local Institution - 727, Craiova, Dolj

Oncolab - Medical Oncology, Craiova, Dolj

Centrul de Oncologie Sf Nectarie - Medical Oncology, Craiova, Dolj

Oncocenter- Oncologie Clinica - Medical Oncology, Timisoara, Timis

Centrul de Oncologie Euroclinic, Iasi, Not set

Spitalul Clinic Judetean De Urgenta Sibiu, Sibiu, Not set

Local Institution - 127, Suceava, Not set

Sigmedical Services S.R.L., Suceava, Not set

University Clinical Center of Nis, Clinic for Pediatrics-Department for Pulmonology, Nis, Vojvodina

Local Institution - 750, Sremska Kamenica, Vojvodina

Local Institution - 753, Belgrade, Not set

Local Institution - 751, Belgrade, Not set

University Clinical Center of Kragujevac, Center for Internal Oncology, Kragujevac, Šumadijski Okrug

Complejo Hospitalario Universitario De Santiago - Oncología Médica, Santiago de Compostela, A Coruña

Hospital Regional Universitario De Málaga, Malaga, Andalucía

Hospital Universitario Central de Asturias, Oviedo, Asturias

Hospital Universitario Son Espases, Palma de Mallorca, Baleares

Local Institution - 686, Santander, Cantabria

Local Institution - 684, Valencia, Valenciana, Comunidad

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitari Dexeus Grupo Quironsalud, Barcelona, Not set

Hospital Universitario Vall d'Hebron - Oncología Médica, Barcelona, Not set

Local Institution - 689, Barcelona, Not set

Hospital General Universitario Gregorio Marañón - Oncología Médica, Madrid, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

M.D. Anderson Center Madrid, Madrid, Not set

Hospital Clínico San Carlos, Madrid, Not set

Hospital Universitario Virgen de la Macarena - Oncología Médica, Sevilla, Not set

Hospital Clinico Universitario De Valencia - Oncologia Médica y Hematologia, Valencia, Not set

Local Institution - 351, Kaohsiung City, Kaohsiung

China Medical University Hospital - Internal Medicine, Taichung City, Taichung Municipality

Chung Shan Medical University Hospital, Taichung City, Taichung

China Medical University Hospital - Internal Medicine, Taichung City, Taichung

Local Institution - 355, Taichung City, Taichung

Local Institution - 354, Taipei City, Taipei

Local Institution - 376, Muang, Chiang Mai

Siriraj Hospital, Bangkok, Krung Thep Maha Nakhon [Bangkok]

Srinagarind Hospital - ACADEMIC CLINICAL RESEARCH OFFICE, Khon Kaen, Not set

Local Institution - 378, Songkhla, Not set

Local Institution - 703, Istanbul, Samsun

Gulhane Training and Research Hospital - Medical Oncology, Ankara, Not set

Dr Abdurrahman Yurtaslan Training and Research Hospital - Medical Oncology, Ankara, Not set

Ankara Liv Hospital, Ankara, Not set

Ankara City Hospital - Medical Oncology, Ankara, Not set

Memorial Ankara Hastanesi Tibbi Onkoloji, Ankara, Not set

Trakya Univ Hastanesi Ic Hastal, Edirne, Not set

Medipol Mega Universite Hastanesi Tibbi Onkoloji, Istanbul, Not set

Goztepe SuleymanYalcin Sehir Hast, Istanbul, Not set

Istanbul Onkoloji Hastanesi Tibbi Onkoloji, Istanbul, Not set

Ege University Medical Faculty - Pulmonary, Izmir, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

Learn More ›

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/29/2025

Locations: Sarah Cannon Research Institute, Denver, Colorado +9 locations

Conditions: Advanced Cancer

Learn More ›

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249

Recruiting

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama +227 locations

ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama

Alaska Oncology and Hematology, Anchorage, Alaska

Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona

Local Institution - 001-807, Scottsdale, Arizona

Local Institution - 001-873-A, Tucson, Arizona

USOR - Arizona Oncology - Tucson - Rudasill, Tucson, Arizona

Local Institution - 001-840-B, Bellflower, California

Beverly Hills Cancer Center, Beverly Hills, California

City of Hope - Duarte (Main Campus), Duarte, California

Local Institution - 001-850-K, Dublin, California

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton, Fullerton, California

Local Institution - 001-840-C, Harbor City, California

University of California San Diego Moores Cancer Center, La Jolla, California

TRIO - Cancer and Blood Specialty Clinic, Los Alamitos, California

Southern California Permanente Medical Group - Los Angeles Medical Center, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Hoag Memorial Hospital Presbyterian - Newport Beach, Newport Beach, California

Local Institution - 001-850-B, Oakland, California

University of California Irvine Medical Center, Orange, California

Local Institution - 001-850-C, Roseville, California

Local Institution - 001-850-J, Sacramento, California

Local Institution - 001-850-D, Sacramento, California

California Cancer Associates for Research and Excellence (cCARE) - San Diego 4S Ranch, San Diego, California

Local Institution - 001-840-A, San Diego, California

Local Institution - 001-850-H, San Francisco, California

Local Institution - 001-850-E, San Francisco, California

Local Institution - 001-850-F, San Jose, California

Local Institution - 001-850-A, San Leandro, California

Ridley - Tree Cancer Center - Santa Barbara, Santa Barbara, California

Local Institution - 001-850-I, Santa Clara, California

Local Institution - 001-884-A, Solvang, California

Kaiser Permanente - Vallejo Medical Center, Vallejo, California

Local Institution - 001-850-G, Walnut Creek, California

USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado

UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado

Local Institution - 001-872-H, Boulder, Colorado

Local Institution - 001-872-E, Colorado Springs, Colorado

Local Institution - 001-872-L, Colorado Springs, Colorado

Local Institution - 001-872-B, Denver, Colorado

Local Institution - 001-951 - A, Denver, Colorado

Local Institution - 001-951 - B, Denver, Colorado

Cancer Centers of Colorado - St. Marys Regional Hospital, Grand Junction, Colorado

SCL Health - Saint Joseph Hospital Cancer Center, Lafayette, Colorado

Local Institution - 001-872-A, Lakewood, Colorado

Local Institution - 001-872-D, Littleton, Colorado

Local Institution - 001-872-K, Lone Tree, Colorado

Local Institution - 001-872-C, Longmont, Colorado

Local Institution - 001-872-J, Parker, Colorado

Local Institution - 001-872-F, Pueblo, Colorado

Local Institution - 001-872-G, Pueblo, Colorado

Local Institution - 001-872-I, Thornton, Colorado

Yale Cancer Center, New Haven, Connecticut

USOR - Medical Oncology Hematology Consultants, Newark, Delaware

Local Institution - 001-929i, Altamonte Springs, Florida

Boca Raton Clinical Research Associates, Inc., Boca Raton, Florida

Local Institution - 001-922A, Bonita Springs, Florida

Local Institution - 001-922D, Bradenton, Florida

Local Institution - 001-929c, Brandon, Florida

Local Institution - 001-922E, Cape Coral, Florida

Local Institution - 001-929g, Clearwater, Florida

Local Institution - 001-926b, Daytona Beach, Florida

SCRI - Florida Cancer Specialists - South Region Research Office, Fort Myers, Florida

Local Institution - 001-922B, Fort Myers, Florida

Local Institution - 001-922C, Fort Myers, Florida

Local Institution - 001-929b, Gainesville, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Local Institution - 001-929m, Lady Lake, Florida

Local Institution - 001-929e, Largo, Florida

Local Institution - 001-929n, Lecanto, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Miami Cancer Institute, Miami, Florida

Local Institution - 001-922F, Naples, Florida

Local Institution - 001-922G, Naples, Florida

Florida Cancer Affiliates - Ocala - Main, Ocala, Florida

Local Institution - 001-929p, Ocala, Florida

Local Institution - 001-929j, Orange City, Florida

Mid Florida Cancer Centers - Orange City, Orange City, Florida

Local Institution - 001-929l, Orlando, Florida

Woodlands Medical Specialists, Pensacola, Florida

Local Institution - 001-922H, Port Charlotte, Florida

Local Institution - 001-929a, Saint Petersburg, Florida

SCRI - Florida Cancer Specialists - North Region Research Office, Saint Petersburg, Florida

Local Institution - 001-922I, Sarasota, Florida

Local Institution - 001-922J, Sarasota, Florida

Local Institution - 001-929h, Spring Hill, Florida

Local Institution - 001-926d, Stuart, Florida

Local Institution - 001-929d, Tampa, Florida

Local Institution - 001-929k, Tavares, Florida

Local Institution - 001-929f, Trinity, Florida

Local Institution - 001-922K, Venice, Florida

Local Institution - 001-922L, Venice, Florida

Local Institution - 001-926c, Vero Beach, Florida

Local Institution - 001-926a, Wellington, Florida

SCRI - Florida Cancer Specialists - East Region Research Office, West Palm Beach, Florida

Local Institution - 001-929o, Winter Park, Florida

University Cancer & Blood Center (UCBC) - Athens, Athens, Georgia

Local Institution - 001-835-C, Austell, Georgia

Local Institution - 001-835-E, Austell, Georgia

Local Institution - 001-835-D, Carrollton, Georgia

Local Institution - 001-835-F, Carrollton, Georgia

Local Institution - 001-835-A, Cartersville, Georgia

Local Institution - 001-835-B, Douglasville, Georgia

Northwest Georgia Oncology Centers Wellstar - Marietta, Marietta, Georgia

Affiliated Oncologists, LLC, Chicago Ridge, Illinois

Local Institution - 001-828, Chicago, Illinois

USOR - Illinois Cancer Specialists - Niles, Niles, Illinois

Memorial Hospital, South Bend, Indiana

University of Iowa, Iowa City, Iowa

University of Kansas Medical Center, Westwood, Kansas

University of Kentucky, Lexington, Kentucky

SCRI - Hematology Oncology Clinic - Baton Rouge, Baton Rouge, Louisiana

MaineHealth Cancer Care - Biddeford, Biddeford, Maine

Local Institution - 001-881-B, Brandywine, Maryland

Maryland Oncology Hematology - Columbia, Columbia, Maryland

Local Institution - 001-881-A, Silver Spring, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Health System, Detroit, Michigan

Local Institution - 001-842-A, Farmington Hills, Michigan

Local Institution - 001-838-F, Coon Rapids, Minnesota

Local Institution - 001-838-E, Edina, Minnesota

Local Institution - 001-875 - D, Edina, Minnesota

Local Institution - 001-838-D, Maplewood, Minnesota

Local Institution - 001-875 - A, Maplewood, Minnesota

Local Institution - 001-838-C, Minneapolis, Minnesota

USOR - Minnesota Oncology - Minneapolis Clinic, Minneapolis, Minnesota

Local Institution - 001-838-G, Minneapolis, Minnesota

Local Institution - 001-822-A, Minneapolis, Minnesota

Masonic Cancer Center, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Metro-Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park, Minnesota

Local Institution - 001-838-B, Saint Louis Park, Minnesota

Local Institution - 001-838-A, Saint Paul, Minnesota

Local Institution - 001-875 - B, Saint Paul, Minnesota

Local Institution - 001-875 - C, Woodbury, Minnesota

Central Care Cancer Center - Bolivar, Bolivar, Missouri

Goldschmidt Cancer Center, Jefferson City, Missouri

Sisters of Charity of Leavenworth Health St. Marys, Billings, Montana

Local Institution - 001-544B, Omaha, Nebraska

Methodist Estabrook Cancer Center, Omaha, Nebraska

Local Institution - 001-544A, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 001-860A, Henderson, Nevada

Local Institution - 001-860C, Henderson, Nevada

Local Institution - 001-860B, Henderson, Nevada

USOR - Comprehensive Cancer Centers of Nevada - Southeast Henderson, Henderson, Nevada

Local Institution - 001-860E, Las Vegas, Nevada

Local Institution - 001-860D, Las Vegas, Nevada

Local Institution - 001-860F, Las Vegas, Nevada

New York Oncology Hematology - Albany Medical Center, Albany, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Local Institution - 001-832, Lake Success, New York

Perlmutter Cancer Center - 34th Street, New York, New York

Local Institution - 001-583, New York, New York

Memorial Sloan Kettering Cancer Center - New York, New York, New York

University of North Carolina Hospitals, Chapel Hill, North Carolina

FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Health Barrett Cancer Center, Cincinnati, Ohio

Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Local Institution - 001-833 - H, Columbus, Ohio

Local Institution - 001-833 - C, Columbus, Ohio

Local Institution - 001-833 - J, Columbus, Ohio

Local Institution - 001-833 - A, Columbus, Ohio

Local Institution - 001-833 - F, Columbus, Ohio

The Ohio State University College of Medicine, Columbus, Ohio

Local Institution - 001-833 - D, Columbus, Ohio

Local Institution - 001-833 - I, Columbus, Ohio

SCRI - Mark H. Zangmeister Cancer Center, Columbus, Ohio

Local Institution - 001-833 - B, Columbus, Ohio

Local Institution - 001-833 - G, Columbus, Ohio

Local Institution - 001-833 - E, Gahanna, Ohio

Kettering Health Cancer Center - Main Campus, Kettering, Ohio

Local Institution - 001-836-A, Kettering, Ohio

Cancer Centers of Southwest Oklahoma - Leah M. Fitch Cancer Center, Lawton, Oklahoma

Local Institution - 001-580, Oklahoma City, Oklahoma

Local Institution - 001-584, Tulsa, Oklahoma

Local Institution - 001-586-A, Bend, Oregon

St. Charles Health System, Bend, Oregon

Willamette Valley Cancer Institute and Research Center - Eugene, Eugene, Oregon

Lehigh Valley Physician Group Hematology Oncology, Allentown, Pennsylvania

Local Institution - 001-837-A, Bethlehem, Pennsylvania

Penn State Cancer Institute, Hershey, Pennsylvania

USOR - Alliance Cancer Specialists - Media (Cancer Center at Riddle Memorial Hospital), Media, Pennsylvania

USOR - Charleston Hematology Oncology Associates, Charleston, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Local Institution - 001-801-G, Gallatin, Tennessee

Local Institution - 001-801-A, Hendersonville, Tennessee

Local Institution - 001-801-D, Hermitage, Tennessee

Local Institution - 001-801-F, Murfreesboro, Tennessee

Local Institution - 001-801-B, Nashville, Tennessee

Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology, Nashville, Tennessee

Local Institution - 001-801-E, Nashville, Tennessee

Local Institution - 001-801-C, Nashville, Tennessee

Local Institution - 001-888-B, Arlington, Texas

USOR - Texas Oncology Dallas Fort Worth West (DFWW) - Arlington South, Arlington, Texas

USOR - Texas Oncology - Austin Central, Austin, Texas

Local Institution - 001-848a, Conroe, Texas

Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Presbyterian Cancer Center Dallas, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

USOR - Texas Oncology Northeast Texas - Denison, Denison, Texas

Texas Oncology - Dallas Fort Worth (DFW) - Fort Worth, Fort Worth, Texas

Oncology Consultants - Texas Medical Center, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 001-935A, Houston, Texas

Local Institution - 001-999, Irving, Texas

Local Institution - 001-935D, Kingwood, Texas

Lumi Research, Kingwood, Texas

USOR - Texas Oncology - Midland Allison Cancer Center, Midland, Texas

START Center for Cancer Care, San Antonio, Texas

Local Institution - 001-935B, Shenandoah, Texas

Local Institution - 001-935C, Spring, Texas

Texas Oncology - Sugar Land, Sugar Land, Texas

Local Institution - 001-935E, Tomball, Texas

Texas Oncology - Northeast Texas Cancer and Research Institute - Tyler, Tyler, Texas

Texas Oncology - Waco, Waco, Texas

Local Institution - 001-919, Fairfax, Virginia

NEXT Virginia, Fairfax, Virginia

Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia

USOR - Virginia Oncology Associates - Newport News, Newport News, Virginia

Local Institution - 001-882-A, Norfolk, Virginia

Local Institution - 001-890-A, Norfolk, Virginia

Virginia Cancer Institute - West End, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver, Washington

University Wisconsin Carbone Cancer Center, Madison, Wisconsin

PanOncology Trials - Rio Piedras Medical Center, San Juan, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

Learn More ›

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

NCT02628067

Recruiting

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Call for Information (Investigational Site 0008), New Brunswick, New Jersey +18 locations

Conditions: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma

Learn More ›

BOLSTER: Learning New Skills to Thrive

NCT06936878

Recruiting

This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/21/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations

Conditions: Gastrointestinal Cancer, Gynecologic Cancer, Advanced Cancer

Learn More ›

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467

Recruiting

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2025

Locations: California Cancer Associates for Research and Excellence, Encinitas, California +32 locations

California Cancer Associates for Research and Excellence, Encinitas, California

University of California San Diego UCSD, La Jolla, California

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

Hoag - Huntington Beach, Newport Beach, California

Regents of the University of Colorado, Aurora, Colorado

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Insitute, Detroit, Michigan

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Stony Brook University, Stony Brook, New York

SCRI Oncology Partners - Nashville, Nashville, Tennessee

NEXT Oncology Virginia, Fairfax, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Institut Jules Bordet, Anderlecht, Not set

UZ Leuven - Campus Gasthuisberg, Leuven, Not set

GZA Hopsitals Campus Sint-Augustinus, Wilrijk, Not set

Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL), Dijon, Not set

Centre Oscar Lambret, Lille, Not set

Centre Leon Berard, Lyon, Not set

Centre Antoine Lacassagne, Nice, Not set

Hopital Lyon Sud, Pierre Benite, Not set

Institut Gustave Roussy, Villejuif, Not set

Ospedale San Gerardo-ASST Monza, Monza, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Gachon University Gil Medical Center, Incheon, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital Beata Maria Ana, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

START - Madrid, Madrid, Not set

Conditions: Advanced Cancer, Breast Cancer

Learn More ›

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

NCT06228326

Recruiting

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1/2, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/14/2025

Locations: XCancer Research Network/Dothan Hematology & Oncology, Dothan, Alabama +10 locations

Conditions: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)

Learn More ›

Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers

NCT06722014

Recruiting

Smartphone Technology to Alleviate Malignant Pain (STAMP) + Cognitive Behavioral Therapy for Pain (STAMP+CBT) The purpose of the study is to develop and refine the mHealth pain-CBT app intervention and carry out a randomized pilot to test the novel mHealth (Mobile health technology) intervention, which harmonizes psychological and pharmacological support for advanced cancer pain. The name of the study smartphone application involved in this study is: -STAMP+CBT

Gender:

ALL

Ages:

22 years and above

Trial Updated:

05/14/2025

Locations: Dana Farber Cancer Institute, Boston, Massachusetts

Conditions: Pain, Pain Syndrome, Advanced Cancer

Learn More ›

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

NCT05004116

Recruiting

This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that causes few or mild side effects in study participants. When the researchers find this dose, we will evaluate it in a different group of participants to find out whether repotrectinib in combination with chemotherapy is an ef... Read More

Gender:

ALL

Ages:

Between 1 year and 25 years

Trial Updated:

05/05/2025

Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

Conditions: Advanced Cancer, Metastatic Solid Tumor

Learn More ›

1 - 12 of 51